The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Merafloxacin     1-ethyl-7-[3- (ethylaminomethyl) pyrrolidin...

Synonyms: CHEMBL6209, AGN-PC-00N6AQ, CI-934, SureCN2110210, KST-1A9178, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CI 934


High impact information on CI 934


Chemical compound and disease context of CI 934


Biological context of CI 934

  • Among the quinolones tested, the most active were found to be CI-934 and ciprofloxacin, which inhibited gyrase full supercoiling activity at concentrations of 100 and 200 micrograms/ml, respectively, while inhibiting cell growth at a concentration of 1 microgram/ml [10].

Associations of CI 934 with other chemical compounds


  1. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Mandell, W., Neu, H.C. Antimicrob. Agents Chemother. (1986) [Pubmed]
  2. Rate of bactericidal activity for Streptococcus faecalis of a new quinolone, CI-934, compared with that of amoxicillin. Yourassowsky, E., Van der Linden, M.P., Lismont, M.J., Crokaert, F., Glupczynski, Y. Antimicrob. Agents Chemother. (1986) [Pubmed]
  3. Activity of CI-934 against gram-positive bacteria. Rolston, K.V., Bodey, G.P. J. Antimicrob. Chemother. (1986) [Pubmed]
  4. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. King, A., Phillips, I. J. Antimicrob. Chemother. (1986) [Pubmed]
  5. Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. Van Caekenberghe, D. J. Antimicrob. Chemother. (1990) [Pubmed]
  6. Comparative chemotherapeutic activity of new fluorinated 4-quinolones and standard agents against a variety of bacteria in a mouse infection model. Sesnie, J.C., Fritsch, P.W., Griffin, T.J., Heifetz, C.L., Leopold, E.T., Malta, T.E., Shapiro, M.A., Vincent, P.W. J. Antimicrob. Chemother. (1989) [Pubmed]
  7. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid. King, A., Shannon, K., Slegg, J., Phillips, I. J. Antimicrob. Chemother. (1986) [Pubmed]
  8. Elimination of antibiotic-resistant plasmids by quinolone antibiotics. Fu, K.P., Grace, M.E., Hsiao, C.L., Hung, P.P. Chemotherapy. (1988) [Pubmed]
  9. Gaps and perspectives of new fluoroquinolones. Neuman, M., Esanu, A. Drugs under experimental and clinical research. (1988) [Pubmed]
  10. Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones. Fu, K.P., Grace, M.E., McCloud, S.J., Gregory, F.J., Hung, P.P. Chemotherapy. (1986) [Pubmed]
  11. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin. Floyd-Reising, S.A., Kelley, S.G., Hindler, J.A., Young, L.S. Diagn. Microbiol. Infect. Dis. (1987) [Pubmed]
WikiGenes - Universities